This contrasts with conclusions from a meta-analysis performed by Noori et al. [54] on results from randomized clinical trials treating patients suffering from esophageal carcinoma with PD-1/PD-L1 inhibitors, which showed that only a CPS = 10 was predictive of a lower rate of mortality when PD-1 inhibitors including pembrolizumab and nivolumab were administered. The gene discussed is CD274; the disease is carcinoma of esophagus.